US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff

$ 750


With nine drugs expected to lose their patents between 2011 and 2016, the US Cholesterol Lowering Agents (Dyslipidemia) Market currently stands at the edge of a major patent cliff. IMARC Group, one of the world’s leading research and advisory firms, expects in its new report” US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” that despite a strong performance of Crestor (Rosuvatation), the avalanche of patent expiries and a thin drug pipeline will erode this market of sales worth more than US$ 8.7 billion in the next six years.

This report provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:

Key Aspects Analyzed:

Understanding the Epidemiology of Dyslipidemia in the US:

Focus of the Analysis:

  • Current and future size of the dyslipidemia patient pool
  • Current and  future prevalence of dyslipidemia
  • Current and future diagnosis rates for dyslipidemia
  • Current and future drug treatment rates for dyslipidemia


Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:

Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors

Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib

Focus of the Analysis for Each Class & Molecule:

  • Drug Overview
  • Historical Sales
  • Key Players and Brands in the Market
  • Patent Expiries and Generic Launch
  • Sales Forecast 


Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:

  • Historical Patent Expiries  and the Evolution of Generic Drugs
  • Historical Value and Volume share of Brands and Generics
  • Future Patent Expiries and Generic  Launches
  • Value and Volume Forecasts for Brands and Generics


Information Sources:

Information has been sourced from both primary and secondary sources:

  • Primary sources include industry surveys and face to face/telephone interviews with industry experts.
  • Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.

1. Research Methodology & Market Definitions
2. Executive Summary
3. Epidemiology
    3.1 Prevalence of Dyslipidemia
    3.2 Diagnosis & Drug Treatment Rates
4. The US Cholesterol Lowering Agents Market
    4.1 Current Trends (2005-2010)
    4.2 Market Forecast (2011-2016)
5. The US Dyslipidimia Market: Performance of Various Classes
    5.1 Statins
        5.1.1 Key Trends (2005-2010)
        5.1.2 Share of Key Players
        5.1.3 Sales & Forecast of Key Molecules
            5.1.3.1 Atorvastatin (Lipitor) Historical Sales & Forecast
            5.1.3.2 Rosuvastatin (Crestor) Historical Sales & Forecast
            5.1.3.3 Simvastatin (Zocor) Historical Sales & Forecast
            5.1.3.4 Pravastatin (Pravachol) Historical Sales & Forecast
            5.1.3.5 Fluvastatin (Lescol) Historical Sales & Forecast
            5.1.3.6 Lovastatin (Mevacor) Historical Sales & Forecast
            5.1.3.7 Pitavastatin (Livalo) Historical Sales & Forecast
    5.2 Fixed Dose Combinations
        5.2.1 Key Trends
        5.2.2 Share of Key Players
        5.2.3 Sales & Forecast of Key Molecules
            5.2.3.1 Ezetimibe/Simvastatin (Vyotrin) Historical Sales & Forecast
            5.2.3.2 ER Niacin/Simvastatin (Simcor) Historical Sales & Forecast
            5.2.3.3 Atorvastatin/Amlodipine (Caduet) Historical Sales & Forecast
            5.2.3.4 ER Naicin/Lapropiprant (Tredaptive) Historical Sales & Forecast
            5.2.3.1 Ezetimibe/Atorvastatin (MK-653C) Sales Forecast
            5.2.3.2 ER Niacin/Laropiprant/Simvastatin (MK-0524B) Sales Forecast
    5.3 Ion Exchange Resins
        5.3.1 Key Trends
        5.3.2 Share of Key Players
        5.3.3 Sales & Forecast of Key Molecules
            5.3.3.1 Colesevelam (Welchol) Historical Sales & Forecast
            5.3.3.2 Cholestyramine (Questran) Historical Sales & Forecast
            5.3.3.3 Colestipol (Colestid) Historical Sales & Forecast
    5.4 Fibrates Market
        5.4.1 Key Trends
        5.4.2 Share of Key Players
        5.4.3 Sales & Forecast of Key Molecules
            5.4.3.1 Fenofibrate (Tricor) Historical Sales & Forecast
            5.4.3.2 Fenofibric Acid (Trilipix) Historical Sales & Forecast
            5.4.3.3 Gemfibrozil (Lopid) Historical Sales & Forecast
    5.5 Other Cholesterol Triglyceride Regulators
        5.5.1 Key Trends
        5.5.2 Share of Key Players
        5.5.3 Sales & Forecast of Key Molecules
            5.5.3.1 Ezetimibe (Zetia) Historical Sales & Forecast
            5.5.3.2 Nicotinic Acid (Niacin/Niaspan) Historical Sales & Forecast
    5.6 Omega-3 Acid Ethyl Esters (Lovaza)
        5.6.1 Key Trends
        5.6.2 Share of Key Players
        5.6.3 Sales Forecast
    5.7 CETP Inhibitors
        5.7.1 Sales Forecast for Key Molecules
            5.7.1.1 Dalcetrapib (RO4607381/JTT-705) Sales Forecast
            5.7.1.2 Anacetrapib (MK-0859) Sales Forecast
6. Genericization in the US Dyslipidemia Market
    6.1 Generic Evolution in the US Dyslipidemia Market
    6.2 Patent Expiries & Size of the Generic Opportunity
    6.3 Forecast for Dyslipidemia Generics
7. Key Company Profile
    7.1 Pfizer
    7.2 Merck & Co
    7.3 Astrazeneca
    7.4 Abbott
    7.5 Glaxosmithkline

 

List of Figures

Figure 3 1: US - Number of Dyslipidemia Patients (in 000’s), 2010, 2015 & 2020
Figure 3 2: US - Diagnosed and Drug Treated Dylipidemia Patients (in %) 2010, 2015, 2020
Figure 4 1: US – Cholesterol Lowering Agents Market - Share by Class (in %), 2005-2010
Figure 4 2: US – Cholesterol Lowering Agents Market Forecast - Share by Class (in %), 2011-2016
Figure 5 1: US - Statins Market (in Million US$), 2005-2010
Figure 5 2: US - Statins Market – Share of Key Players (in %), 2005-2010
Figure 5 3: US – Statins Market - Share by Molecule (in %) 2005-2010
Figure 5 4: US - Statins Market Forecast – Share by Molecule (in %), 2011-2016
Figure 5 5: US – Atorvastatin Sales (in Million US$), 2005-2010
Figure 5 6: US – Atorvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 7: US – Rosuvastatin Sales (in Million US$), 2005-2010
Figure 5 8: US - Rosuvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 9: US –- Simvastatin Sales (in Million US$), 2005-2010
Figure 5 10: US –Simvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 11: US - Pravastatin Sales (in Million US$), 2005-2010
Figure 5 12: US - Pravastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 13: US –Fluvastatin Sales (in Million US$), 2005-2010
Figure 5 14: US - Fluvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 15: US – Lovastatin Sales (in Million US$), 2005-2010
Figure 5 16: US – Lovastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 17: US - Pitavastatin Sales (in Million US$), 2010
Figure 5 18: US –Pitavastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 19: US – Fixed Dose Combinations Market (in Million US$), 2005-2010
Figure 5 20: US - Fixed Dose Combinations Market – Share of Key Players (in %),
Figure 5 21: US – Fixed Dose Combinations Market - Share by Molecule (in %) 2005-2010
Figure 5 22: US - Fixed Dose Combinations Market Forecast - Share by Molecule (in %), 2011-2016
Figure 5 23: US – Ezetimibe/Simvastatin Combination Sales (in Million US$), 2005-2010
Figure 5 24: US – Ezetimibe/Simvastatin Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 25: US – ER Niacin/Simvastatin Combination Sales (in Million US$), 2005-2010
Figure 5 26: US – ER Niacin/Simvastatin Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 27: US –Atorvastatin/Amlodipine Combination Sales (in Million US$), 2005-2010
Figure 5 28: US - Atorvastatin/Amlodipine Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 29: US – ER Naicin/Lapropiprant Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 30: US – Ezetimibe/Atorvastatin Combination Sales Forecast (in Million US$), Launch - 2016
Figure 5 31: US – ER Niacin/Laropiprant/Simvastatin Combination Sales Forecast (in Million US$), Launch -2016
Figure 5 32: US – Ion Exchange Resins Market (in Million US$), 2005-2010
Figure 5 33: US - Ion Exchange Resins Market – Share of Key Players (in %),
Figure 5 34: US – Ion Exchange Resins Market - Share by Molecule (in %) 2005-2010
Figure 5 35: US - Ion Exchange Resins Market Forecast – Share by Molecule (in %), 2011-2016
Figure 5 36: US – Colesevelam Sales (in Million US$), 2005-2010
Figure 5 37: US – Colesevalam Sales Forecast (in Million US$), 2011-2016
Figure 5 38: US – Cholestyramine Sales (in Million US$), 2005-2010
Figure 5 39: US – Cholestyramine Sales Forecast (in Million US$), 2011-2016
Figure 5 40: US – Colestipol Sales (in Million US$), 2005-2010
Figure 5 41: US – Colestipol Sales Forecast (in Million US$), 2011-2016
Figure 5 42: US - Fibrates Market (in Million US$), 2005-2010
Figure 5 43: US - Fibrates Market – Share of Key Players (in %),
Figure 5 44: US – Fibrates Market - Share by Molecule (in %) 2005-2010
Figure 5 45: US - Fibrates Market Forecast - Share by Molecule (in %), 2011-2016
Figure 5 46: US – Fenofibrate Sales (in Million US$), 2005-2010
Figure 5 47: US – Fenofibrate Sales Forecast (in Million US$), 2011-2016
Figure 5 48: US – Fenofibric Acid Sales (in Million US$), 2005-2010
Figure 5 49: US – Fenofibric Acid Sales Forecast (in Million US$), 2011-2016
Figure 5 50: US – Gemfibrozil Sales (in Million US$), 2005-2010
Figure 5 51: US – Gemfibrozil Sales Forecast (in Million US$), 2011-2016
Figure 5 52: US – Cholesterol Triglyceride Regulators Market (in Million US$), 2005-2010
Figure 5 53: US - Cholesterol Triglyceride Regulators Market – Share of Key Players (in %),
Figure 5 54: US – Cholesterol Triglyceride Regulators Market - Share by Molecule (in %) 2005-2010
Figure 5 55: US - Cholesterol Triglyceride Regulators Market Forecast - Share by Molecules (in %), 2011-2016
Figure 5 56: US – Ezetimibe Sales (in Million US$), 2005-2010
Figure 5 57: US – Ezetimibe Sales Forecast (in Million US$), 2011-2016
Figure 5 58: US - Nicotinic Acid Sales (in Million US$), 2005-2010
Figure 5 59: US - Nicotinic Acid Sales Forecast (in Million US$), 2011-2016
Figure 5 60: US – Omega-3 Acid Ethyl Esters Market (in Million US$), 2005-2010
Figure 5 61: US - CETP Inhibitors Market Forecast - Share by Molecules (in %), Launch - 2016
Figure 5 62: US – Dalcetrapib Sales Forecast (in Million US$), Launch - 2016
Figure 5 63: US – Anacetrapib Sales Forecast (in Million US$), Launch - 2016
Figure 6 1: US – Dyslipidemia Market – Patent Expiries of Drugs 2005-2010
Figure 6 2: US – Dyslipidemia Market – Share of Brands & Generics by Volume (in %) 2005-2010
Figure 6 3: US – Dyslipidemia Market – Share of Brands & Generics by Sales (in %) 2005-2010
Figure 6 4: US – Dyslipidemia Market Forecast – Key Patent Expiries, 2011-2016
Figure 6 5: US – Dyslipidemia Market Forecast – Share of Brands and Generics by Volume (in %), 2011-2016
Figure 6 6: US – Dyslipidemia Market Forecast – Share of Brands & Generics by Value, 2011-2016

 

List of Tables

Table 1 1: US - Dyslipidemia Market: Market Definitions
Table 2 1: US: Dyslipidemia Market Forecast by Class & Molecule (in Million US$), 2010, 2013 & 2016
Table 3 1: US – Diagnosed and Drug Treated Dylipidemia Patients (in 000’s), 2010, 2015, 2020
Table 4 1: US – Cholesterol Lowering Agents Market - Sales by Class (in Million US$), 2005-2010
Table 4 2: US – Cholesterol Lowering Agents Market Forecast - Sales by Class (in Million US$), 2011-2016
Table 5 1: US - Statins Market – Sales of Key Players (in Million US$),
Table 5 2: US – Statins Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 3: US – Statins Market Forecast – Sales By Molecule (in Million US$), 2011-2016
Table 5 4: US - Atorvastatin - Drug Overview
Table 5 5: US: Rosuvastatin - Drug Overview
Table 5 6: US- Simvastatin - Drug Overview
Table 5 7: US- Statins Market: Pravastatin - Drug Overview
Table 5 8: US- Fluvastatin - Drug Overview
Table 5 9: US - Lovastatin - Drug Overview
Table 5 10: US - Pitavastatin - Drug Overview
Table 5 11: US - Fixed Dose Combinations Market – Sales of Key Players (in Million US$),
Table 5 12: US – Fixed Dose Combinations Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 13: US – Fixed Dose Combinations Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 14: US - Ezetimibe/Simvastatin Combination- Drug Overview
Table 5 15: US- ER Niacin/Simvastatin Combination - Drug Overview
Table 5 16: US - Atorvastatin/Amlodipine Combination - Drug Overview
Table 5 17: US - ER Naicin/Lapropiprant Combination - Drug Overview
Table 5 18: US - Ezetimibe/Atorvastatin Combination - Drug Overview
Table 5 19: US - ER Niacin/Laropiprant/Simvastatin Combination - Drug Overview
Table 5 20: US - Ion Exchange Resins Market – Sales of Key Players (in Million US$),
Table 5 21: US – Ion Exchange Resins Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 22: US – Ion Exchange Resins Market Forecast –Sales by Molecule (in Million US$), 2011-2016
Table 5 23: US - Colesevalam - Drug Overview
Table 5 24: US - Cholestyramine - Drug Overview
Table 5 25: US - Colestipol - Drug Overview
Table 5 26: US - Fibrates Market – Sales of Key Players (in Million US$), 2005-2010
Table 5 27: US – Fibrates Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 28: US – Fibrates Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 29: US - Fenofibrate - Drug Overview
Table 5 30: US - Fenofibric Acid - Drug Overview
Table 5 31: US - Gemfibrozil - Drug Overview
Table 5 32: US - Cholesterol Triglyceride Regulators Market – Sales of Key Players (in Million US$),
Table 5 33: US – Cholesterol Triglyceride Regulators Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 34: US – Cholesterol Triglyceride Regulators Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 35: US - Ezetimibe - Drug Overview
Table 5 36: US - Nicotinic Acid - Drug Overview
Table 5 37: US - Omega-3 Acid Ethyl Esters - Drug Overview
Table 5 38: US – Omega-3 Acid Ethyl Esters Market Forecast (in Million US$), 2011-2016
Table 5 39: US – CETP Inhibitors Market Forecast – Sales by Molecules (in Million US$), Launch -2016
Table 5 40: US - Dalcetrapib - Drug Overview
Table 5 41: US: Anacetrapib - Drug Overview
Table 6 1: US – Dyslipidemia Market – Brand & Generic Sales (in Million US$), 2005-2010
Table 6 2: US – Dyslipidemia Market – Sales of Molecules One Year Before Patent expiry (in Million US$), 2011-2016
Table 6 3: US – Dyslipidemia Market Forecast – Brand & Generic Sales (in Million US$), 2011-2016


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Special Prices


    IMARC provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations
  • For more information, feel free to contact us.